Accumulating evidence suggests that a subpopulation of breast cancer cells, referred to as cancer stem cells (CSCs), have the ability to propagate a tumor and potentially seed new metastases. Furthermore, stimulation of an epithelialto-mesenchymal transition by factors like transforming growth factor-b (TGFb) is accompanied with the generation of breast CSCs. Previous observations indicated that bone morphogenetic protein-7 (BMP7) antagonizes the protumorigenic and prometastatic actions of TGFb, but whether BMP7 action is mechanistically linked to breast CSCs has remained elusive. Here, we have studied the effects of BMP7, BMP2 and a BMP2/7 heterodimer on the formation of human breast CSCs (ALDH À/low CSC subpopulation. In keeping with these in vitro observations, pretreatment of cancer cells with BMPs for 72 h prior to systemic inoculation of the cancer cells inhibited the formation of bone metastases. Collectively, our data support the notion that breast CSCs are involved in bone metastasis formation and describe heterodimeric BMP2/7 as a powerful TGFb antagonist with anti-metastatic potency.
Introduction
Breast cancer is the most common type of cancer among females, and metastatic spread to bone is detected in up to 80% of patients with advanced disease (Coleman, 1997; Jemal et al., 2010) .
The development of novel therapies for bone metastases has been limited and generally failed to improve patient overall survival. Too often initial beneficial responses in (bone) metastases are followed by re-growth of therapy-resistant malignant lesions (Winquist et al., 2009) .
For over 150 years, it has been hypothesized that only a minority of cells within a tumor are responsible for tumor growth and development (Wicha et al., 2006) . Only recently has it become possible to isolate and characterize these tumor-initiating cells from solid tumors, including those of the breast (Al-Hajj et al., 2003) and prostate (Collins et al., 2005; . As few as 20 sorted cells from human primary breast cancer with a particular stem/progenitor phenotype could initiate tumor formation in the mammary gland of immunodeficient mice, whereas much larger numbers (10 4 -10 5 ) of cells depleted of that particular phenotype did not (Ginestier et al., 2007) . Many of these isolated tumor-initiating cells share surface markers with somatic stem/progenitor cells of their tissue of origin and share the characteristics of selfrenewal, high proliferative potential, differentiation along one or several diverse lineages (asymmetric division), and homing, to allow cells to migrate and seek their niche. For these reasons, tumor-initiating cells are also referred to as 'cancer stem cells (CSCs)' (Reya et al., 2001) . The concept of CSCs underscores the importance of targeting the correct cells for cancer therapy, as eliminating only the rapidly dividing, more differentiated transit-amplifying cells by chemo-or radiotherapy is not likely to result in successful longterm remission if the less differentiated and slower proliferating CSCs remain to repopulate the tumor. Therefore, it has been postulated that the CSC population in solid cancers can be potentially affected by the so-called differentiation-inducing agents (Buijs et al., 2007a (Buijs et al., , 2007c van der Pluijm, 2010) .
By sorting breast cancer cells for a normal mammary stem cell phenotype (CD44 þ /CD24 À/low ), Al-Hajj et al. (2003) were the first to isolate a subpopulation that was enriched for breast CSCs. The tumorigenic potential of CD44 þ /CD24 À/low CSCs could be further increased by introducing an additional (fluorescence-activated cell sorting-based) viable cell sorting step, the selection of cells based on high activity of aldehyde dehydrogenase (ALDH) (Ginestier et al., 2007) . Furthermore, a number of genes appear to be co-expressed in CD44 þ /CD24
À/low breast cancer cells, including vimentin, connective tissue growth factor, plasminogen activator inhibitor-1, osteonectin, as well as transforming growth factor-b (TGFb) receptor type-II (TbRII) (Shipitsin et al., 2007) . In fact, many of the genes actively transcribed by CD44 þ / CD24
À/low cells were classical TGFb targets and associated with a mesenchymal, migratory phenotype. Moreover, the presence of this gene signature correlated with poor prognosis. In addition, treatment of CD44 þ / CD24 À/low /TbRII þ metastatic mammary cancer cells with a TGFb receptor kinase inhibitor resulted in a reversal of their mesenchymal into a more epithelial CD44
þ phenotype (Shipitsin et al., 2007) . In line with these observations, Mani et al. (2008) demonstrated that an epithelial-to-mesenchymal transition (EMT) generates cells with properties of stem cells in the normal and transformed mammary epithelium. TGFb-induced EMT in immortalized human mammary epithelial cells was associated with the acquisition of the CD44 þ /CD24 À/low phenotype and mesenchymal traits, and increased ability to form mammospheres, a property associated with mammary epithelial stem cells showing evidence of the involvement of EMT in breast CSC formation (Mani et al., 2008) . In addition, overexpressing of the E-cadherin repressor SNAI1 or the prometastatic transcription factor TWIST, both wellknown TGFb targets, enhanced the in vivo tumorigenic potential in V12H-Ras-transformed immortalized human mammary epithelial cells (Mani et al., 2008) . More recently, further evidence was provided regarding a mechanistic link between EMT and stem cell signature in prostate (Kong et al., 2010) , colorectal and pancreatic cancer (Wellner et al., 2009) , thus supporting the concept that EMT is not only important for invasion, but also induces stem/progenitor characteristics in multiple carcinomas. Taken together, these studies provide evidence that TGFb is important in regulating the dynamics of cell populations by favoring stem cell self-renewal and inhibiting the commitment to differentiation (Tan et al., 2009) .
Bone morphogenetic proteins (BMPs) are members of the TGFb super-family and typically appear as dimeric disulfide-linked growth factors that may regulate epithelial plasticity in normal and cancer cells (ten Dijke, 2006; Buijs et al., 2007b) . In malignant human glioma, Smad-dependent BMP4 signaling was able to trigger a reduction in CD133
þ CSCs, resulting in a decrease in tumorigenicity and tumor formation (Piccirillo et al., 2006) . In addition, Klose et al. (2011) showed that systemic BMP7 treatment inhibited tumor growth in an experimental mouse model of glioma. Furthermore, an aggressive clone of the human MCF-7 breast cancer cell line showed, besides reduced BMP7 expression, upregulation of CD44 and downregulation of CD24 (Uchino et al., 2010) , indicative of a CSC phenotype. We have demonstrated previously that BMP7 inhibited TGFb-induced EMT, stimulated the opposite process, a mesenchymal-to-epithelial transition, and inhibited bone metastasis formation in vivo (Buijs et al., 2007a (Buijs et al., , 2007b . To date, the effects of BMPs on breast CSCs have remained elusive.
Here, we evaluated whether two different BMP homodimers (BMP2 and BMP7), and a recently described BMP2/7 heterodimer, can affect the size of the ALDH hi /CD44 hi /CD24 À/low breast CSC subpopulation in vitro and affect bone metastasis formation in vivo.
Results
Heterodimeric and homodimeric BMP molecules differentially stimulate BMP signaling and target gene expression For studies of BMP signaling in human breast cancer cells, the BMP-responsive element (BRE) coupled to firefly luciferase (BREluc) was stably transfected into the MDA-MB-231-Frt3 host cell line, generating the MDA-MB-231/BREluc cell line. This reporter cell line was used to compare the BMP2 and BMP7 homodimers, and the BMP2/7 heterodimer, for their ability to induce BMP signaling ( Figure 1a ). All BMPs dose dependently induced BMP signaling as expected. The BMP2/7 heterodimer was clearly more potent than BMP2 and BMP7 at all concentrations tested (Po0.001; Figure 1a ).
Co-incubation of BMPs with the BMP antagonist Noggin resulted in a strong and significant inhibition of BMP signaling after challenge with BMP2 (96% inhibition, Po0.001) and BMP7 (69% inhibition, Po0.01) (Figure 1b) . By contrast, heterodimeric BMP2/7 activity was affected only marginally (30% inhibition, Po0.05; Figure 1b) .
Previously, we have shown that MDA-MB-231 breast cancer cells express relatively high amounts of Noggin (Schwaninger et al., 2007) . A Noggin small interfering RNA significantly further increased Smad-dependent BMP signaling under the BMP2-stimulated conditions (BMP2, þ 52%, Po0.001), but no significant effects were observed under the BMP7-and BMP2/7-stimulated conditions (BMP7, þ 18%, NS; BMP2/7, þ 14%, NS) when compared with an non-targeted small interfering RNA (Supplementary Figure 1) .
The BRE of the luciferase reporter construct (BREluc) is part of the Id1 promoter, a classic BMP-target gene. All three BMPs strongly stimulated Id1 mRNA expression (Po0.001; Figure 1c ). In line with the BMP reporter data (Figure 1a ), BMP2/7 heterodimers are more potent inducers of the expression of the classical BMP-target genes Id1 and Smad7 (Po0.001; Figure 1c ).
Smad-dependent TGFb reporter activity-dose-and time-dependent effects The MDA-MB-231/CAGAluc2 cells were first characterized by performing a dose response (0.01-10 ng/ml) by using three TGFb isoforms (TGFb 1 , TGFb 2 and TGFb 3 ). No significant differences were observed between the TGFb isoforms regarding stimulation of Smad-dependent TGFb signaling, and a concentration of 1 ng/ml was found to evoke a sub-maximal response (Supplementary Figure 2) , and was used in all subsequent experiments. In the presence or absence of 1 ng/ml TGFb 2 , BMP7 (5-500 ng/ml) dose dependently inhibited Smad-dependent TGFb signaling (Supplementary Figure 3) . As BMP7 at 50 ng/ml inhibited Smaddependent TGFb signaling to sub-maximal levels, this concentration was used in the next experiments to test whether the effects of BMP7 on TGFb signaling are time-dependent. Addition of TGFb time dependently increased CAGAluc2 reporter activity within the first 12 h (up to 12.8-fold induction at 12 h), after which the relative induction slightly diminished with time (up to 3.2-fold induction at 72 h) (Supplementary Figure 4a) . When BMP7 was co-incubated with TGFb, the inhibitory effects of BMP7 on Smad-dependent TGFb signaling increased with time (from 10% inhibition after 4 h to 58% and 64% inhibition after 48 and 72 h of coincubation, respectively) (Supplementary Figure 4b) . In a head-to-head comparison experiment, inhibition of TGFb-induced, Smad-mediated signaling by the BMP2/ 7 heterodimer (À53%, Po0.001) was more pronounced than its homodimeric BMP2 (À11%, Po0.01) or BMP7 (À44%, Po0.001) counterparts ( Figure 2 ). It is important to note that comparable data were obtained when BMP2, BMP7 and BMP2/7 were co-incubated with the other TGFb isoforms (TGFb 1 and TGFb 3 ) ( Supplementary Figures 5a and b) .
Next, we evaluated whether pre-incubation with BMP7 antagonizes TGFb signaling. Simultaneous addition of TGFb and BMP7 resulted in a 42% inhibition of TGFb signaling as expected (Supplementary Figure 6 ), whereas pre-incubation with BMP7 prior to TGFb challenge blocked TGFb signaling to an even greater extend (up to 58% and 76% inhibition after 24 or 48 h of BMP7 pre-incubation, respectively).
Subsequently, we studied whether the effects of BMP7 pre-incubation are reversible. Removal of BMP7 prior to adding TGFb 2 still resulted in significant inhibition of TGFb signaling (Supplementary Figure 7) .
The BMP type-I receptor inhibitor LDN193189 was used to test whether the inhibitory effects of BMP7 on TGFb signaling are BMP signaling-dependent. Treatment with LDN193189 2 h prior to BMP7 stimulation could completely block BMP7-induced, Smad-dependent BMP signaling (Supplementary Figure 8a) as expected. In addition, treatment with LDN193189 was also able to completely block the inhibitory effects of BMP7 on Smad-dependent TGFb signaling (Supplementary Figure 8b ). Figure 9) . Since BMP7 and BMP2/7 significantly inhibited TGFb signaling, and BMPs strongly induce the expression of inhibitory Smad7 (Figure 1c) , we evaluated whether upregulation of Smad7 may account for the inhibitory effects on TGFb signaling by using knockdown of Smad7 by short-hairpin RNA (Supplementary Figure 10) . However, no differences were observed in the Smad7 knockdown versus mock-transfected clones (Supplementary Figure 10) .
Heterodimeric and homodimeric BMP molecules differentially affect cancer cell migration
The effect of the BMP2 and BMP7 homodimers, and the BMP2/7 heterodimer, on the migratory behavior of breast cancer cells was determined by using a Boyden Chamber migration assay (Petersen et al., 2010) . Pretreatment of MDA-MB-231 breast cancer cells for 48 h with BMP2, BMP7 and BMP2/7 significantly inhibited both basal and TGFb-stimulated migration (Po0.001 for all; Figure 3 ). BMP2 and BMP2/7 more strongly reduced migration than BMP7 (Po0.05).
TGFb and BMPs differentially affect the formation of ALDH
À/low breast cancer stem/progenitor cells A potential strategy for the identification of cancer cells with a stem/progenitor cell-like phenotype involves selection based on high ALDH enzyme activity by using the ALDEFLUOR assay (Cheung et al., 2007; Ginestier et al., 2007; . The size of the population with high ALDH enzymatic activity in MDA-MB-231 breast cancer cells was 24.4% of the total population (Figure 4a ). Incubation with TGFb 2 for 72 h significantly increased the ALDH hi subpopulation by 71% (Po0.01; Figure 4a ). Comparable results were obtained with the other TGFb isoforms (TGFb 1 and TGFb 3 , data not shown). Conversely, incubation for 72 h with any of the three BMPs tested decreased the size of the ALDH hi subpopulation (BMP2, À42%, NS; BMP7, À47%, Po0.05; BMP2/7, À51%, Po0.05; Figure 4a ). In the presence of TGFb 2 , co-incubation with BMPs, particularly BMP2/7, could still reduce the size of the ALDH hi subpopulation of cancer cells as compared with TGFb 2 alone (BMP2, À44%, Po0.05; BMP7, À38%, Po0.05; BMP2/7, À63%; all Po0.01; Figure 4a) Figures 4b and c) .
It is currently unknown which of the 19 ALDH isoforms are responsible for the high ALDH activity assessed by the ALDEFLUOR assay. Therefore, we examined the mRNA expression levels of candidate ALDH isoforms. Subsequently, we analyzed whether BMPs affect the mRNA expression levels of ALDH isoforms. ALDH3A2 was the most abundantly expressed ALDH isoform (Supplementary Figure 12a) . Its expression was inhibited upon incubation for 24 h with BMPs, particularly BMP2/7 (BMP2, À45%, Po0.05; BMP7, À27%, NS; BMP2/7, À58%, Po0.05; Supplementary  Figure 3b) . Of the three BMPs tested, BMP2/7 was the most potent in lowering the mRNA expression levels of five ALDH isoforms with highest expression at the basal level (ALDH3A2, À58%; ALDH6A1, À60%; ALDH7A1, À54%; ALDH9A1, À33%; ALDH18A1, À15%; Supplementary Figure 12b ).
BMP treatment and bone metastasis formation in a preclinical model As BMPs inhibited the generation of human breast cancer cells with an ALDH hi /CD44 hi /CD24 À/low stem/ progenitor phenotype, we further tested whether BMP pretreatment of osteotropic breast cancer cells affected the metastatic competence in a preclinical bone metastasis model. As expected (van der Pluijm et al., 2005; Buijs et al., 2007a) , vehicle-treated cells readily formed multiple detectable bone metastases (Figures 5a-c) .
When compared with mice receiving vehicle-treated cancer cells, pretreatment of cancer cells with BMP2 or BMP2/7 resulted in an inhibition of the number of de novo formed bone metastases at the end of the experiment, that is, 4 weeks after cancer cell inoculation (Po0.05; Figure 5b ). In fact, significant differences could already be observed at week 1 (Figure 5b) .
Furthermore, the metastatic tumor burden was significantly decreased from week 2 onwards, particularly in animals receiving heterodimeric BMP2/7-pretreated cancer cells (Po0.01; Figure 5c ). Similarly, BMP2 pre treatment resulted in a significant and sustained reduction of the number of metastases (Po0.01), whereas in mice receiving BMP7-pretreated cells there was a strong inhibitory trend toward a reduced tumor burden (P ¼ 0.08; Figure 5c ).
Discussion
An increasing body of basic and clinical studies has provided evidence of self-renewing, stem/progenitor-like Generally, CSCs constitute a minority of neoplastic cells within a tumor and are defined by their ability to propagate a tumor and potentially seed new metastases (Reya et al., 2001) . Relatively small subpopulations of osteotropic cancer cell with stem/progenitor features appeared critical initiators of tumor growth at orthotopic sites, whereas the majority of the cancer cells that were depleted of this phenotype did not form tumors 
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In human breast cancer, the CD44 þ /CD24 À/low CSC signature was linked with a mesenchymal, migratory phenotype. Even more, TGFb-induced EMT may render breast cancer cells with properties of stem cells and even therapy resistance (Mani et al., 2008; Creighton et al., 2009; Polyak and Weinberg, 2009; Singh and Settleman, 2010; van der Pluijm, 2010) . Strikingly, BMP7 treatment can antagonize TGFb-induced EMT, and inhibit breast cancer growth and bone metastasis formation in vivo (Buijs et al., 2007a (Buijs et al., , 2007b . Nonetheless, the direct effects of BMPs on breast CSCs have not been addressed.
In the current study, we found that BMP2/7 heterodimers were significantly more potent than homodimeric BMP2 and BMP7 counterparts in stimulating BMP signaling and BMP-target gene expression. Comparable data were found in non-transformed cells, that is, a higher potency of the BMP2/7 heterodimer in stimulating BMP2/7 inhibits the breast cancer stem cell subpopulation JT Buijs et al osteoblast differentiation in vitro and in vivo (Zhu et al., 2004; Koh et al., 2008) . Furthermore, our data showed that co-incubation with the BMP antagonist Noggin lead to a complete block of BMP2 activity. By contrast, the inhibitory effect of Noggin on BMP7, and particularly BMP2/7, was less prominent. Osteolytic MDA-MB-231 breast cancer cells express relatively high amounts of Noggin (Schwaninger et al., 2007) , which directly contributes to an osteolytic bone phenotype through inhibition of BMP-mediated effects on bone formation by osteoprogenitors. The observed increased potency of BMP2/7 (compared with BMP2 or BMP7 alone) may, therefore, at least in part be caused by the increase in bioavailability due to the diminished efficacy of locally produced Noggin. Of note, BMP7 inhibits epithelial proliferation, branching morphogenesis and ductal budding in the normal development of the prostate, and is also associated with decreased Notch signaling (Grishina et al., 2005) , a critical pathway during morphogenesis of epithelial tissues. In this context, the BMP antagonist Noggin can have a key regulatory role in BMP4 and BMP7 action in tissue epithelial stem cells (Cook et al., 2007) . Strikingly, the BMP2/7 heterodimer was a more potent inhibitor of TGFb signaling than its BMP2 and BMP7 homodimeric counterparts. Moreover, we show for the first time that treatment with BMPs (that is, BMP2, BMP7 and BMP2/7) decreased the subpopulation of breast cancer cells with a stem/progenitor cell phenotype (ALDH hi /CD44 hi /CD24 À/low ) whereas TGFb had an opposite effect. Interestingly, a 3-day pretreatment with BMP2 or BMP2/7 significantly reduced the formation of skeletal metastases and total tumor burden, with a clear inhibitory trend for BMP7.
Whereas both BMP2 and BMP7 strongly inhibited ALDH activity and a breast CSC phenotype (ALDH   hi   /  CD44 hi /CD24 À/low ), BMP7 strongly inhibited TGFb signaling and marginally affected migration. Conversely, BMP2 mildly inhibited TGFb signaling but strongly reduced migration. This suggests that the observed inhibition of bone metastasis is due to a reduction of the CSC pool size and/or impaired invasiveness rather than inhibition of TGFb signaling per se.
In solid and hematologic cancers, the CSC population can be selected by virtue of high ALDH or ALDE-FLUOR activity. ALDH activity is probably a determinant of cell survival through their ability to detoxify many potentially cytotoxic molecules, contributing to drug resistance (Alison et al., 2010) . To date, it has remained unclear which of the 19 ALDH isoforms contribute to the observed high ALDEFLUOR activity. Our transcriptional profiling data reveal that all tested BMPs lowered the mRNA expression levels of the most abundantly expressed ALDH isoform, ALDH3A2. It was shown previously that the ALDH isoform ALD-H1A1 was associated with poor prognosis in breast cancer (Ginestier et al., 2007) . Despite relatively low basal expression levels of ALDH1A1 in MDA-MB-231 cells, BMP2 (À75%), BMP7 (À28%) and BMP2/7 (À28%) were still able to further reduce its expression (data not shown).
In vitro studies have shown that co-expression of BMP2 and BMP7 can lead to the formation of biologically active heterodimeric BMP2/7 molecules (Hazama et al., 1995; Israel et al., 1996; Zhao et al., 2005) . Although the physiological role of heterodimeric BMP molecules still awaits validation in vivo, it has been shown that forced expression or treatment with BMP2/7 heterodimers potently stimulated bone formation in vitro as well as in vivo (Hazama et al., 1995; Israel et al., 1996; Zhu et al., 2004; Zhao et al., 2005) , thus providing a rationale for the development of BMP heterodimeric molecules for clinical use in bone fracture healing. In line with these observations, a recent publication on a BMP2/6 heterodimer also demonstrated the superiority of the heterodimer over its homodimeric BMP2 or BMP6 counterparts in the differentiation induction of human embryonic stem cells in vitro (Valera et al., 2010) .
CSCs appear more resistant to several conventional therapies than their non-CSC counterparts (Woodward et al., 2007; Li et al., 2008; Creighton et al., 2009) , underscoring the need for developing CSC-directed therapies. Although breast CSCs may arise as the result of EMT (Mani et al., 2008; Hollier et al., 2009; Wellner et al., 2009; Kong et al., 2010; Singh and Settleman, 2010) , the current findings support the notion that this intrinsic epithelial plasticity of cancer cells can also be exploited to inhibit their invasiveness and metastatic potential by using selected BMPs. It provides the rationale for the clinical development of differentiation-inducing compounds as a novel strategy to target CSCs or their supportive microenvironment in advanced breast cancer.
Materials and methods

Cell line and culture conditions
The human breast cancer cell line MDA-MB-231 (ATCC, Rockville, MD, USA) and the luciferase-expressing boneseeking clone MDA-MB-231-B/Luc þ were cultured in Dulbecco's modified Eagle's medium containing 4.5 g/l glucose and supplemented with 10% FCII (Hyclone, Etten-Leur, The Netherlands) as described previously (Buijs et al., 2007a) . All cell lines were tested for Mycoplasma contamination by PCR prior to use.
Luciferase reporter gene constructs
The CAGA 12 reporter construct consists of 12 Smad3/Smad4-binding sequences (CAGA boxes) and was coupled to a codonoptimized firefly luciferase (luc2) to detect intracellular Smaddependent TGFb signaling (Dennler et al., 1998) . The CAGA boxes confer TGFb stimulation to a heterologous promoter reporter construct, whose activity depends on the binding of activated Smad3/Smad4 transcription factor complexes (Dennler et al., 1998) .
The BRE 4 -luciferase construct, which is based on the mouse Id1 promoter and coupled to firefly luciferase, was used to study the presence and functionality of BMP receptors (Korchynskyi and ten Dijke, 2002) .
Generation of isogenic cell lines by targeted integration
Stable cell lines were generated by using the Flp-In system (Invitrogen, Breda, The Netherlands) according to manufacturer's protocol and as described previously (Notting et al., 2005) . In short, an MDA-MB-231-Flp-in host cell line (MDA-MB-231-Frt3) was generated by a stable introduction of a single copy of an Flp-Recombinase target (FRT) site as an integral part of an antibiotic resistance gene (blasticidin) in the genome of these cells (5 mg/ml blasticidin was added to the culture medium). The MDA-MB-231-Frt3 cells were subsequently used for the generation of isogenic stable cell lines by targeted recombination using an FRT-targeting vector and an Flp-recombinase expression vector. For consistency, this MDA-MB-231-Frt3 host cell line was used in all the other experiments described in this paper unless otherwise stated.
The FRT-targeting vectors used were pGl4-FRT vectors (Invitrogen), containing CAGA 12 -MLP-luc2 or BRE 4 -luc sequences with a hygromycin resistance gene. Owing to Flptargeted recombination at the genomic FRT site, this vector was incorporated in the genome. Simultaneously, a shift in antibiotic resistance was introduced allowing positive selection for integrants in the genomic FRT site only and negative selection for random integrants in one single step. This method allows the generation of isogenic stable cell lines, which only differ in the sequence inserted in the genomic FRT site, thereby eliminating the need for clonal selection. The generated stable cell lines MDA-MB-231-Frt3{MLP-CAGA-luc2} (MDA-MB-231/CAGAluc2) and MDA-MB-231-Frt3{BRE-luc} (MDA-MB-231/BREluc) were cultured in presence of 0.35 mg/ml hygromycin (Invitrogen).
It is important to note that the codon optimized luciferase luciferase2 (luc2) to CAGA significantly improved the sensitivity of the detection of Smad3/4-dependent TGFb signaling.
The Flp-in method used should allow for the generation of isogenic stable cell lines, yielding cell lines with similar characteristics and responsiveness for each stable transfection. To test this, we repeated the stable transfection and tested a newly generated clone, MDA-MB-231-Frt3{CAGA 12 MLP-luc2} clone#2. When compared with MDA-MB-231-Frt3{CA-GA 12 MLP-luc2}clone#1, similar responses were observed for all three TGFb isoforms (TGFb 1-3 , data not shown).
Luciferase reporter assay system From stably transfected MDA-MB-231 cell lines, cells were seeded at a density 15 000 cells/cm 2 in Dulbecco's modified Eagle's medium with 10% FCII in 24-well plates. On the subsequent day, the cells were stimulated with TGFb 2 (used at a concentration of 1 ng/ml unless otherwise stated; R&D Systems, Abingdon, UK) and/or BMP2, BMP7 or BMP2/7 (all used at a concentration of 50 ng/ml unless otherwise stated; R&D Systems), and/or Noggin (used at a concentration of 100 ng/ml unless otherwise stated; R&D Systems). After incubation for 30 h, or as stated otherwise, luciferase activity was quantified as relative light units (RLUs) as described previously (Buijs et al., 2007a) .
Quantitative real-time RT-PCR RNA isolation, cDNA synthesis and quantitative real-time reverse transcription-PCR were performed as described earlier (van den Hoogen et al., 2010) using the primers as described in Supplementary Materials and Methods.
Migration assay MDA-MB-231 cells were pre-incubated for 48 h with BMP2, BMP7 or BMP2/7 (50 ng/ml), or vehicle (0.1% bovine serum albumin). Cells were detached using trypsin-EDTA and reseeded in 6.5-mm-diameter Transwell inserts containing 8.0 mm pores (Costar, Cambridge, MA, USA). BMP2, BMP7 or BMP2/7 proteins were added to the medium again and costimulated with TGFb 2 (5 ng/ml) or vehicle (0.1% bovine serum albumin). Cells that migrated through the pores were stained with crystal violet. Three photographs were acquired by using a color CCD camera mounted on a Nikon Eclipse 610 at a 20-fold magnification and cells were counted (Petersen et al., 2010; .
ALDEFLUOR assay and flow cytometry
The ALDH activity of cells was determined by using the ALDEFLUOR assay kit (StemCell Technologies, Grenoble, France) according to the manufacturer's protocol . The ALDH substrate was added to the cells and was converted by intracellular ALDH into a fluorescent product. Cells were concurrently labeled with the fluorescent antibodies CD44-APC and CD24-PE (R&D Systems), and analyzed by using the FACS Calibur2 (BD Biosciences, Alphen aan den Rijn, The Netherlands) and FCS express De Novo software (Los Angeles, CA, USA).
Animals
Female athymic nude mice (Balb/c nu/nu) were purchased from Charles River (L'Arbresle, France). The animals were housed in individual ventilated cages under sterile condition, and sterile food and water were provided ad libitum. The animal experiments were approved by the local committee for animal health, ethics and research of Leiden University and conducted in accordance with the European Communities Council Directive 86/609/EEC. BMP2-, BMP7-, BM2/7-or vehicle-pretreated MDA-MB-231/Luc þ cells (van der Pluijm et al., 2005) were harvested at 70-80% confluence. A single-cell suspension of 10 5 cells/100 ml of phosphate-buffered saline was injected into the left cardiac ventricle and cancer cell growth was monitored weekly by whole body bioluminescent imaging (BLI) using an intensified charge-coupled device (I-CCD) video camera of the in vivo Imaging System (IVIS100; Xenogen, Alameda, CA, USA) as described previously (Buijs et al., 2007a; . Values are expressed as RLUs in photons/s.
After the experimental periods, mice were killed by cervical dislocation. Tibiae with tumors were dissected and processed for further histomorphometrical and immunohistochemical analysis as described earlier (Buijs et al., 2007a) .
Statistical analysis
All experimental data are presented as mean±s.e.m. All in vitro experiments were performed in triplicate and repeated at least once, and statistical evaluations were performed by one-way analysis of variance, or two-way when applicable, by using least significant difference post hoc testing. The in vivo experiment was performed with eight animals per group and statistical evaluation was performed by two-way analysis of variance.
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